390 related articles for article (PubMed ID: 23633202)
1. Relation between circulating levels of 25(OH) vitamin D and parathyroid hormone in chronic kidney disease: quest for a threshold.
Metzger M; Houillier P; Gauci C; Haymann JP; Flamant M; Thervet E; Boffa JJ; Vrtovsnik F; Froissart M; Stengel B; Ureña-Torres P;
J Clin Endocrinol Metab; 2013 Jul; 98(7):2922-8. PubMed ID: 23633202
[TBL] [Abstract][Full Text] [Related]
2. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
Taal MW; Thurston V; McIntyre NJ; Fluck RJ; McIntyre CW
Kidney Int; 2014 Aug; 86(2):407-13. PubMed ID: 24429404
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis.
Del Valle E; Negri AL; Aguirre C; Fradinger E; Zanchetta JR
Hemodial Int; 2007 Jul; 11(3):315-21. PubMed ID: 17576296
[TBL] [Abstract][Full Text] [Related]
4. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD.
Ureña-Torres P; Metzger M; Haymann JP; Karras A; Boffa JJ; Flamant M; Vrtovsnik F; Gauci C; Froissart M; Houillier P; Stengel B;
Am J Kidney Dis; 2011 Oct; 58(4):544-53. PubMed ID: 21803465
[TBL] [Abstract][Full Text] [Related]
5. Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial.
Wetmore JB; Kimber C; Mahnken JD; Stubbs JR
Br J Nutr; 2016 Dec; 116(12):2074-2081. PubMed ID: 28065190
[TBL] [Abstract][Full Text] [Related]
6. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
Ennis JL; Worcester EM; Coe FL; Sprague SM
J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620
[TBL] [Abstract][Full Text] [Related]
7. The effect of some medications given to CKD patients on vitamin D levels.
Yuste C; Quiroga B; de Vinuesa SG; Goicoechea MA; Barraca D; Verdalles U; Luño J
Nefrologia; 2015; 35(2):150-6. PubMed ID: 26300508
[TBL] [Abstract][Full Text] [Related]
8. On-line haemodiafiltration improves response to calcifediol treatment.
Pérez-García R; Albalate M; de Sequera P; Alcázar R; Puerta M; Ortega M; Corchete E
Nefrologia; 2012 Jul; 32(4):459-66. PubMed ID: 22652556
[TBL] [Abstract][Full Text] [Related]
9. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
[TBL] [Abstract][Full Text] [Related]
10. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
11. The importance of parathyroid hormone and vitamin D status in the treatment of osteoporosis and renal insufficiency.
Drinka PJ
J Am Med Dir Assoc; 2004; 5(6):382-6. PubMed ID: 15530176
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of serum vitamin D levels, status, and determinants in populations with and without chronic kidney disease not requiring renal dialysis: a 24-hour urine collection population-based study.
Guessous I; McClellan W; Kleinbaum D; Vaccarino V; Zoller O; Theler JM; Paccaud F; Burnier M; Bochud M;
J Ren Nutr; 2014 Sep; 24(5):303-12. PubMed ID: 25030223
[TBL] [Abstract][Full Text] [Related]
13. Body adiposity predictors of vitamin D status in nondialyzed patients with chronic kidney disease: A cross-sectional analysis in a tropical climate city.
Barreto Silva MI; Cavalieri VV; Lemos CC; Klein MR; Bregman R
Nutrition; 2017 Jan; 33():240-247. PubMed ID: 27692990
[TBL] [Abstract][Full Text] [Related]
14. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
16. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Zisman AL; Hristova M; Ho LT; Sprague SM
Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D status and its association with mineral and bone disorder in a multi-ethnic chronic kidney disease population.
Ngai M; Lin V; Wong HC; Vathsala A; How P
Clin Nephrol; 2014 Oct; 82(4):231-9. PubMed ID: 25161115
[TBL] [Abstract][Full Text] [Related]
18. Predictors of vitamin D status in predialysis chronic kidney disease patients: a cross-sectional analysis in a high ultraviolet climate.
Petchey WG; Johnson DW; Hawley CM; Isbel NM
J Ren Nutr; 2012 Jul; 22(4):400-8. PubMed ID: 22074789
[TBL] [Abstract][Full Text] [Related]
19. The influence of renal function on vitamin D metabolism in the very elderly.
Van Pottelbergh G; Matheï C; Vaes B; Adriaensen W; Gruson D; Degryse JM
J Nutr Health Aging; 2013 Feb; 17(2):107-11. PubMed ID: 23364486
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study.
Hjelmesaeth J; Hofsø D; Aasheim ET; Jenssen T; Moan J; Hager H; Røislien J; Bollerslev J
Cardiovasc Diabetol; 2009 Feb; 8():7. PubMed ID: 19187564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
